KLKB1 Gene Editing for Long-Acting Hereditary Angioedema Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Hereditary angioedema (HAE) is characterized by recurrent episodes of severe swelling due to excess bradykinin levels, which are not adequately addressed by existing treatments targeting the kallikrein-kinin pathway.
Innovation Solution
The CRISPR/Cas system is used to knockout the KLKB1 gene, reducing prekallikrein production and subsequently bradykinin levels, thereby mitigating swelling episodes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If existing treatments targeting the kallikrein-kinin pathway are used, then bradykinin levels are temporarily reduced, but the treatment requires repeated administrations and does not provide long-term relief
Solution Approach 1:
The CRISPR/Cas9 system performs preliminary genetic modification by knocking out the KLKB1 gene before the disease manifests or worsens. This preliminary action creates a permanent reduction in prekallikrein production, eliminating the need for repeated treatments and providing long-term relief from HAE symptoms.
Solution Approach 2:
The genetic modification enables the body's own cells to stop producing prekallikrein autonomously. Once the KLKB1 gene is knocked out, the cell permanently ceases prekallikrein synthesis without requiring external intervention, making the treatment self-sustaining and eliminating the need for repeated administrations.
2Reliability
If CRISPR/Cas9 is used to knockout the KLKB1 gene, then permanent reduction in bradykinin production is achieved, but potential off-target effects and safety concerns arise
Solution Approach 1:
The patent implements multiple layers of feedback control to ensure safety: (1) The guide RNA is designed with high specificity to the KLKB1 gene sequence, (2) Cas9 activity is regulated by requiring both guide RNA and Cas9 protein presence, (3) Cell death mechanisms are activated if excessive off-target cutting occurs, providing a safety feedback loop that limits harmful effects.
Solution Approach 2:
The patent optimizes multiple parameters to reduce off-target effects: (1) The guide RNA sequence is carefully selected and validated for specificity, (2) The Cas9 protein concentration and exposure time are controlled, (3) Delivery methods are optimized to ensure precise targeting. These parameter changes collectively minimize off-target effects while maintaining reliable gene knockout.
3Productivity
If multiple guide RNAs are used to target different exons of KLKB1, then gene knockout efficiency is improved, but the complexity of the composition increases
Solution Approach 1:
The KLKB1 gene is segmented into multiple target sites across different exons (exons 1, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, or 15). Multiple guide RNAs are designed to target these different segments, ensuring that at least one guide RNA will effectively knock out the gene regardless of which specific exon is disrupted. This segmentation strategy improves knockout efficiency while distributing the complexity across multiple simple, modular guide RNA components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a long-term or permanent reduction in bradykinin production, significantly reducing the frequency and severity of HAE attacks and associated symptoms.
Implementation Method 1
a guide RNA with an RNA-guided DNA binding agent such as the CRISPR/Cas system to substantially reduce or knockout expression of the KLKB1 gene
Implementation Method 2
a guide sequence comprising at least 95%, 90%, or 85% identical to a sequence selected from SEQ ID NOs: 15, 8, and 41
Data Source
AI summary
Compositions and methods for editing, e.g., introducing double-stranded breaks, within the KLKB1 gene are provided. Compositions and methods for treating subjects having hereditary angioedema (HAE), are provided.